Abbott (ABT) announced plans to spin off its Nutrition business into a new publicly traded company via a tax-free distribution to shareholders. The Nutrition unit, with ~$8.5B in annual sales and brands like Similac and Ensure, will operate independently. Abbott will focus on its higher-growth medtech and diagnostics portfolio (~$42B sales). Completion expected by end of 2027, subject to approvals.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
